Navigation Links
Agendia Launches TargetPrint(R) for Breast Cancer Patients
Date:9/4/2008

is processed at Agendia's Clinical Laboratory Improvement Amendments (CLIA) certified and the College of American Pathology (CAP) accredited laboratory.

About Agendia

Agendia is a world leader in molecular cancer diagnostics. The company markets four products based on its breakthrough platform for tumor gene expression profiling and has several new diagnostic tests under development. Agendia was the first company to receive FDA clearance for a breast cancer test, MammaPrint(R), that predicts the risk of breast cancer recurrence. In addition, the company collaborates with pharma companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information on Agendia, please visit http://www.agendia.com.

MEDIA CONTACTS

U.S. Media Contact: EU and non-U.S. Media:

Kelly Connor Hans Herklots

Vice President Head Corporate Communications

Ogilvy Public Relations Worldwide Agendia

+1.212.880.5328 Office +31.20.462.1557 Office

+1.609.221.5785 Mobile +31.620.083.509 Mobile

Kelly.connor@ogilvypr.com hans.herklots@agendia.com


'/>"/>
SOURCE Agendia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Aon eSolutions Launches Clinical Trials Module
2. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
3. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
4. Impliant Launches Less-Invasive Version of Patented TOPS(TM) Spine System
5. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
6. Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO08
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University
9. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)
10. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
11. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 WHEN: ... EDTLOCATION: Online, complimentary registration available at: ... Leader Archana Vidyasekar and Visionary Innovation Research ... WiFi-like wireless electricity, self-assembling materials, nanobots and ... technologies which will transform our lives in ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... Mass. and SYDNEY, July 27, 2011 HeartWare International, Inc. ... second quarter and six months ended June 30, 2011, after ... 4, 2011. A conference call with management is ... August 4, 2011 (being 7:00 am Australian Eastern Standard Time, ...
... July 27, 2011 Varian Medical Systems (NYSE: ... of $0.83 per diluted share in the third quarter of ... year-ago quarter.  Revenues for the quarter were $649 million, up ... on a constant currency basis.  Order backlog at the end ...
Cached Medicine Technology:HeartWare to Report Financial Results for Second Quarter of 2011 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 7
(Date:10/22/2014)... 2014 (HealthDay News) -- Two sisters in high school ... Ilina and Medha Krishen use electronic stethoscopes, which ... trouble in breathing patterns or heartbeats. Ilina, a ... wanted to find a way to detect early lung ... an electronic stethoscope, Ilina recorded one breath cycle each ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 ... fertilization (IVF) -- the incubation of embryos in a laboratory ... the vagina, new research suggests. Scientists from the United ... might sharply cut costs for pricey IVF procedures among certain ... those who don,t live near big-city assisted reproduction centers, the ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. ... officially tightened guidelines for health workers treating Ebola patients, now ... of a respirator at all times. The U.S. Centers ... rules after two Dallas nurses contracted Ebola while caring for ... national Thomas Eric Duncan. Nina Pham is currently being treated ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts to ... figures and forecasts on the global medical markets. , ... the Worldwide Medical Market Forecasts to 2019 ... the worldwide medical market to reveal key insights into ... for 2010-2019, covering each country market individually, allowing you ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
Breaking Medicine News(10 mins):Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... pH monitoring and esophageal manometry are the gold standards ... disorders, respectively. Intraluminal refluxate can be recognized by US ... of gastric content into the esophagus and the visualization ... seen in 45 of 500 (9%) adults. GER and/or ...
... treating early-stage prostate cancer, intensity modulated radiation,therapy (IMRT) ... when compared to 3-D conformal,proton therapy (3D-CPT), but ... both treatments, according to a study,released in the ... Oncology*Biology*Physics, the official,journal of the American Society for ...
... Grows Total Number of WellBound Programs to ... WellBound, the first,company focused exclusively on ... spectrum of self-care dialysis therapies, today,announced the ... center.,Located is Sacramento, CA, this "Center of ...
... of Process and Standards,Development, Clear Method to ... A legal analysis released,today by The George ... (GW) and the Robert Wood Johnson Foundation (RWJF) ... physician ranking systems used,by health plan provider networks. ...
... 9 MyCoupons, LLC has furthered its,movement in helping ... the recent release of its Coupon Codes for a ... creating a buzz among web,retailers. MyCoupons.com recently announced ... research when customers redeem coupons from their site,with thousands ...
... Girls as young as three,and women as old as ... dying two types of death," says Christine Karumba,Country Director, Women ... the physical and the emotional death. The physical death is ... the emotional death is where,you no longer see signs of ...
Cached Medicine News:Health News:IMRT better for sparing bladder when treating prostate cancer 2Health News:WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA 2Health News:WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA 3Health News:New Analysis Underscores Legality of Physician Ranking and Public Reporting Systems When Used by Health Insurers to Improve Health Care Quality 2Health News:New Analysis Underscores Legality of Physician Ranking and Public Reporting Systems When Used by Health Insurers to Improve Health Care Quality 3Health News:New Analysis Underscores Legality of Physician Ranking and Public Reporting Systems When Used by Health Insurers to Improve Health Care Quality 4Health News:MyCoupons, LLC Enlists Clients into the Fight Against Breast Cancer 2Health News:Women for Women International Congolese Country Director, Christine Karumba, Speaks Out About the Rape Epidemic in the Democratic Republic of the Congo. 2
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
... Bridge assembly allows internal or ... cooling coil allows rapid cool-down ... within approximately 10 C of ... is only 5.7 inches wideideal ...
Medicine Products: